Document:

Exhibit 4.1

 

THE BANK OF NEW YORK MELLON

NEW YORK’S FIRST BANK-FOUNDED 1784 BY ALEXANDER HAMILTON

 

 

2 HANSON PLACE, 12TH FLOOR, BROOKLYN,
N.Y. 11217

 

 

 

August 29, 2017

 

Hennion & Walsh, Inc.

2001 Route 46, Waterview Plaza

Parsippany, New Jersey 07054

 

Smart Trust 337

 

Dear Sirs:

The Bank of New York
Mellon is acting as trustee for the series of Smart Trust set forth above (the “Trust”). We enclosed a list
of the Securities to be deposited in the Trust on the date hereof. The prices indicated therein reflect our evaluation of such
Securities as of close of business on August 28, 2017, in accordance with the valuation method set forth in the Standard Terms
and Conditions of Trust and Trust Agreement. We consent to the reference to The Bank of New York Mellon as the party performing
the evaluations of the Trust Securities in the Registration Statement (No. 333-218547) filed with the Securities and Exchange Commission
with respect to the registration of the sale of the Trust Units and to the filing of this consent as an exhibit thereto.

 

 

	 	Very truly yours,
	 	 
	 	/s/ GERARDO CIPRIANO
	 	Gerardo Cipriano
	 	Vice PresidentExhibit 4.3

 

Consent of Independent Registered
Public Accounting Firm

We consent to the
reference made to our firm under the caption “Independent Registered Public Accounting Firm” in Part B of the Prospectus
and to the use of our report dated August 29, 2017, in this Registration Statement (Form S-6 No. 333-218547) of Smart Trust 337,
comprising Smart Trust, Portfolio of Closed-End Fund Opportunities Trust, Series 13.

 

/s/ Grant
Thornton LLP

 

Chicago, Illinois

August 29, 2017Exhibit 10.17

 

ASSIGNMENT

 

WHEREAS: MEDICIS PHARMACEUTICAL CORPORATION,
a corporation organized under the laws of Delaware (hereinafter ASSIGNOR), is an owner of certain patent rights pursuant to that
certain Development and License Agreement between ASSIGNOR and ASSIGNEE (defined below), dated October 9, 2011 (hereinafter AGREEMENT);
and

 

WHEREAS: ASSIGNOR desires to assign
to SOL-GEL TECHNOLOGIES LTD., a corporation organized under the laws of the Country of Israel (hereinafter ASSIGNEE) ASSIGNOR'S
entire interest in and to a US patent application # 13/537,646, titled: "Stabilized Topical Formulations Containing Core-Shell
Microcapsules" (the "PATENT").

 

NOW, THEREFORE, for good and valuable
consideration provided by ASSIGNEE to ASSIGNOR, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and
transfers to ASSIGNEE, its successors, legal representatives, or assigns, ASSIGNOR'S full and exclusive rights, titles and interests
to the PATENT, and to any additional legal protections to be obtained for said PATENT or any continuations, continuations-in-part,
divisions, renewals, extensions, substitutions, replacements, or reissues thereof, and every priority right that is or may be predicated
upon or arise from the PATENT, or any legal equivalent of any thereof in any country for the full term or terms for which the same
may be granted.

 

SAID ASSIGNOR hereby further covenants
that ASSIGNOR has full right to convey the entire right, title, and interest herein sold, assigned, transferred, and set over herein.

 

AND SAID ASSIGNOR further covenants that
ASSIGNOR will, at any time, when reasonably called upon to do so by the ASSIGNEE, its successors, legal representatives, or assigns,
at ASSIGNEE'S cost and expense, communicate thereto any facts known to him relating to said PATENT; execute and deliver any and
all lawful papers (including, but not limited to, granting powers of attorney and executing inventor declarations for continuations-in-part
and reissues of patent applications hereby assigned); make all rightful oaths, affidavits, or declarations; testify in any legal
proceedings, mediations, arbitrations, or other proceedings; and perform all other reasonable lawful acts that may be deemed by
ASSIGNEE necessary or desirable to obtain, secure, and/or vest the benefit of the rights herein assigned, and perfect the title
to said PATENT and all related rights thereto in the name of and for the benefit for the ASSIGNEE, its successors, legal representatives,
or assigns, and to assist or enable the ASSIGNEE, its successors, legal representatives, or assigns to enforce, protect, or otherwise
benefit from the rights in said, applications and patents hereby granted.

 

ASSIGNEE hereby grants to ASSIGNOR and
ASSIGNOR'S affiliates a non-exclusive, transferable, sub-licensable, royalty-free, perpetual, license to practice those inventions
claimed under the PATENT.

 

    	 	 	 

     

    

 

This ASSIGNMENT shall be binding upon ASSIGNOR'S
heirs, executors, administrators, successors, and/or assigns.

 

	Date: 8/16/13	/s/
	 	MEDICIS PHARMACEUTICAL CORPORATION

 

I hereby accept the above assignment for
and on behalf/of the ASSIGNEE

 

	Date: August 8, 2013	/s/ Alon Seri-Levy
	 	SOL-GEL TECHNOLOGIES LTD.Exhibit 4.1

 

PROMISSORY
NOTE

 

Dated:
May 31, 2017

 

FOR
VALUE RECEIVED, and intending to be legally bound, Peninsula Acquisition Corporation, a Delaware corporation (the “Maker”)
with an address at 2255 Glades Road, Suite 324A, Boca Raton, Florida 33431, hereby unconditionally and irrevocably promises to
pay to the order of Mark Tompkins, an individual (the “Payee”) with an address at Apt. 1, Via Guidino 23, 6900
Lugano, Paradiso, Switzerland, in lawful money of the United States of America, the sum of any and all amounts that the Payee
may advance to the Maker or any other third parties on behalf of the Maker as set forth on Schedule A attached hereto,
which may be amended from time to time as funds are advanced (the “Principal Amount”) on or before the date
(the “Maturity Date”) that the Maker (or a wholly owned subsidiary of the Maker) consummates a business combination
with a private company in a reverse merger or reverse takeover transaction or other transaction after which the Maker would
cease to be a shell company (as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended) (“Transaction”).
In the event a Transaction is consummated, the proceeds received by the Maker or a subsidiary of the Maker shall first be used
to repay the entire outstanding unpaid Principal Amount and the accrued unpaid interest on this Note.

 

Interest
shall accrue on the outstanding Principal Amount of this Promissory Note on the basis of a 360-day year from the date upon which
funds were advanced until paid in full at the rate of six percent (6%) per annum, and shall be due and payable on the Maturity
Date, or the prepayment date, if any, whichever is earlier. This Promissory Note may be prepaid in whole or in part
at any time or from time to time prior to the Maturity Date.

 

For
purposes of this Promissory Note, an “Event of Default” shall occur if the Maker shall: (i) fail to pay the
entire Principal Amount of this Promissory Note when due and payable, (ii) admit in writing its inability to pay any of its monetary
obligations under this Promissory Note, (iii) make a general assignment of its assets for the benefit of creditors, or (iv) allow
any proceeding to be instituted by or against it seeking relief from or by creditors, including, without limitation, any bankruptcy
proceedings.

 

In
the event that an Event of Default has occurred, the Payee or any other holder of this Promissory Note may, by notice to the Maker,
declare this entire Promissory Note to be forthwith immediately due and payable, without presentment, demand, protest or further
notice of any kind, all of which are hereby expressly waived by the Maker.  In the event that an Event of Default consisting
of a voluntary or involuntary bankruptcy filing has occurred, then this entire Promissory Note shall automatically become due
and payable without any notice or other action by Payee.  Commencing five days after the occurrence of any Event of
Default, the interest rate on this Note shall accrue at the rate of eighteen percent (18%) per annum.

 

The
non-exercise or delay by the Payee or any other holder of this Promissory Note of any of its rights hereunder in any particular
instance shall not constitute a waiver thereof in that or any subsequent instance.  No waiver of any right shall be
effective unless in writing signed by the Payee, and no waiver on one or more occasions shall be conclusive as a bar to or waiver
of any right on any other occasion.

 

Should
any part of the indebtedness evidenced hereby be collected by law or through an attorney-at-law, the Payee or any other holder
of this Promissory Note shall, if permitted by applicable law, be entitled to collect from the Maker all reasonable costs of collection,
including, without limitation, attorneys’ fees.

 

     

     

    

 

All
notices and other communications must be in writing to the address of the party set forth in the first paragraph hereof and shall
be deemed to have been received when delivered personally (which shall include via an overnight courier service) or, if mailed,
three (3) business days after having been mailed by registered or certified mail, return receipt requested, postage prepaid. The
parties may designate by notice to each other any new address for the purpose of this Promissory Note.

 

Maker
hereby forever waives presentment, demand, presentment for payment, protest, notice of protest, and notice of dishonor of this
Promissory Note and all other demands and notices in connection with the delivery, acceptance, performance and enforcement of
this Promissory Note.

 

This
Promissory Note shall be binding upon the successors and assigns of the Maker, and shall be binding upon, and inure to the benefit
of, the successors and assigns of the Payee.

 

This
Promissory Note shall be governed by and construed in accordance with the internal laws of the State of Delaware.  

 

[The
remainder of this page has been intentionally left blank.]

 

    	 	2	 

     

    

 

IN
WITNESS WHEREOF, the undersigned Maker has executed this Promissory Note as of the date first written above.

 

	 	MAKER:
	 	 
	 	PENINSULA ACQUISITION CORPORATION

 

	 	By: 	/s/ Ian Jacobs
	 	 	Ian Jacobs
	 	 	President

 

    	 	3	 

     

    

 

Schedule
A

 

(as
of June 30, 2017)

 

	 	 	Amount Advanced	 	 	Date of Advance	 
	 	 	$	11,625	 	 	May
                                         9, 2017
 
	 
	 	 	$	15,000	 	 	June
                                                                                                                                     28, 2017	 
	Aggregate Principal Amount	 	$	26,625	 	 		 

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]